The latest information for August 5, 2021


To view this email online, paste this link into your browser:
[link removed]





([link removed])

Thursday, August 5, 2021

Vertex Moves Ahead with Phase 3 Trials of

Once-Daily Triple Combination Therapy

After positive Phase 2 trial results, Vertex announced the company is moving forward with the development of a potential once-daily triple combination therapy. Two Phase 3 trials will begin later this year and will compare this once-daily therapy to Trikafta, which was recently expanded to include children ages 6 through 11. ([link removed])

Read more about the trial » ([link removed])

CDC Updates Mask Guidance

([link removed])

The CDC has recommended ([link removed]) that all people wear masks indoors in areas where COVID-19 is spreading quickly — regardless of their vaccination status, and that those with a weakened immune system or underlying medical condition might choose to wear a mask regardless of level of transmission in their area. The updated guidance is based on an increase in the number of cases among fully vaccinated people. Research has shown that fully vaccinated people can be infected and infect others. Learn more in our ([link removed]) COVID-19 Community Q&A » ([link removed])

CF Community Advocates for CF Program Funding

Many states have wrapped up their annual budget process for Fiscal Year 2022. This year, the Foundation remained focused on protecting against cuts to state programs that support both adults and children living with CF. Community members weighed in to ensure that lawmakers across the country understand the importance of these programs, and as a result of our efforts, CF programs in numerous states including New York and Pennsylvania received full or increased funding. Sign up for advocacy alerts for more opportunities to advocate » ([link removed])

Register for our Sinus Disease Research Webinar

([link removed])

Join us Wednesday, August 25 at 7 p.m. ET ([link removed]) to learn about the latest research addressing this important topic, including studies looking at the impact of highly effective modulators on sinus disease and sinus surgery outcomes. Plus, have an opportunity to ask your sinus research-related questions to CF researchers Daniel Beswick, MD, from UCLA, and Anna Zemke, PhD, from the University of Pittsburgh, during an audience Q&A. Unable to watch live? All those who register will receive a link to the recording after the event.

Save your seat » ([link removed])

DONATE ([link removed])

Cystic Fibrosis Foundation
4550 Montgomery Ave, Suite 1100N
Bethesda, Maryland 20814

www.cff.org ([link removed])



4550 Montgomery Avenue, Suite 1100N | Bethesda, MD 20814 US

This email was sent to [email protected].
To ensure that you continue receiving our emails,
please add us to your address book or safe list.

manage your preferences ([link removed])
opt out ([link removed]) using TrueRemove(r).

Got this as a forward? Sign up ([link removed]) to receive our future emails.
email powered by Emma(R)
[link removed]